Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to ...

Vertex Pharmaceuticals (NASDAQ: VRTX) was on track to become one of this year's biotech winners, with the shares climbing 27% from January through a peak in November. The company, the global ...

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $408.18, moving +0.72% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 1.1%.

Vertex Pharmaceuticals (VRTX ... Vertex is expected to post earnings of $4 per share for the current quarter, representing a year-over-year change of -4.8%. Over the last 30 days, the Zacks ...

Dec 19 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new ... She has a master's degree in English literature and post graduate diploma in broadcast journalism. Future of Healthcategory ...

Vertex Pharmaceuticals is trying to diversify its product portfolio. One of the programs it's working on aims to treat pain in a few contexts. There's reason to believe that it won't be effective ...